Citations

Clear

3942 citation(s) found for "To, Van".

Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma
Winden, Annemieke W. J. Opstal‐van, Haan, Hugoline G. de , Hauptmann, Michael , Schmidt, Marjanka K. , Russell, Nicola S. , Janus, Cécile P.M. , Krol, Augustinus D. G. , Baan, Frederieke H. van der , Bruin, Marie L. De , Eggermond, Anna M. van, Haiman, Christopher A., Sawyer, Elinor J. , Hooning, Maartje J. , Peto, Julian , Orr, Nick , Easton, Douglas F. , Strong, Louise C. , Cooke, Rosie, Swerdlow, Anthony J. , Leeuwen, Flora E. van , de Haan, Hugoline G , De Bruin, Marie L , Dennis, Joe , Pharoah, Paul D P , Swerdlow, Anthony J , Schmidt, Marjanka K , Broeks, Annegien , Anton‐Culver, Hoda , Cox, Angela , Devilee, Peter , Couch, Fergus J. , Pharoah, Paul D.P. , Aleman, Berthe M.P. , Bhatia, Smita , Robison, Leslie L. , Sawyer, Elinor J , Orr, Nick

Mayo Clinic

Blood | December 21, 2018 | Volume: 133 | Issue: 10 | Pages: 1130-1139

10.1182/blood-2018-07-862607 | PMID 30573632 Get It

AbstractFemale Hodgkin lymphoma (HL) patients treated with chest radiotherapy (RT) have a very high risk of breast cancer. The contribution of genetic factors to this risk is unclear. We therefore examined 211 155 germline single-nucleotide polymorphisms (SNPs) for gene-radiation interaction on breast cancer risk in a case-only analysis including 327 breast cancer patients after chest RT for HL and 4671 first primary breast cancer patients. Nine SNPs showed statistically significant interaction with RT on breast cancer risk (false discovery rate, <20%), of which 1 SNP in the PVT1 oncogene attained the Bonferroni threshold for statistical significance. A polygenic risk score (PRS) composed of these SNPs (RT-interaction-PRS) and a previously published breast cancer PRS (BC-PRS) derived in the general population were evaluated in a case-control analysis comprising the 327 chest-irradiated HL patients with breast cancer and 491 chest-irradiated HL patients without breast cancer. Patients in the highest tertile of the RT-interaction-PRS had a 1.6-fold higher breast cancer risk than those in the lowest tertile. Remarkably, we observed a fourfold increased RT-induced breast cancer risk in the highest compared with the lowest decile of the BC-PRS. On a continuous scale, breast cancer risk increased 1.4-fold per standard deviation of the BC-PRS, similar to the effect size found in the general population. This study demonstrates that genetic factors influence breast cancer risk after chest RT for HL. Given the high absolute breast cancer risk in radiation-exposed women, these results can have important implications for the management of current HL survivors and future patients.
Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL
Wendorff, Agnieszka A. , Quinn, S. Aidan , Rashkovan, Marissa , Madubata, Chioma J. , Ambesi‐Impiombato, Alberto , Litzow, Mark R. , Tallman, Martin S. , Paietta, Elisabeth , Paganin, Maddalena , Basso, Giuseppe , Loh, Mignon L. , Rabadán, Raúl , Vlierberghe, Pieter Van , Ferrando, Adolfo A. , Basso, Giuseppe , Rashkovan, Marissa , Loh, Mignon L , Van Vlierberghe, Pieter , Gastier‐Foster, Julie M.

Mayo Clinic

Cancer Discovery | December 19, 2018 | Volume: 9 | Issue: 3 | Pages: 436-451

10.1158/2159-8290.cd-18-1005 | PMID 30567843 Get It

Abstract The plant homeodomain 6 gene (PHF6) is frequently mutated in human T-cell acute lymphoblastic leukemia (T-ALL); however, its specific functional role in leukemia development remains to be established. Here, we show that loss of PHF6 is an early mutational event in leukemia transformation. Mechanistically, genetic inactivation of Phf6 in the hematopoietic system enhances hematopoietic stem cell (HSC) long-term self-renewal and hematopoietic recovery after chemotherapy by rendering Phf6 knockout HSCs more quiescent and less prone to stress-induced activation. Consistent with a leukemia-initiating tumor suppressor role, inactivation of Phf6 in hematopoietic progenitors lowers the threshold for the development of NOTCH1-induced T-ALL. Moreover, loss of Phf6 in leukemia lymphoblasts activates a leukemia stem cell transcriptional program and drives enhanced T-ALL leukemia-initiating cell activity. These results implicate Phf6 in the control of HSC homeostasis and long-term self-renewal and support a role for PHF6 loss as a driver of leukemia-initiating cell activity in T-ALL. Significance: Phf6 controls HSC homeostasis, leukemia initiation, and T-ALL leukemia-initiating cell self-renewal. These results substantiate a role for PHF6 mutations as early events and drivers of leukemia stem cell activity in the pathogenesis of T-ALL. This article is highlighted in the In This Issue feature, p. 305
Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need
Quiroz, Yakeel T. , Albensi, Benedict C. , Astell, Arlene , Babiloni, Claudio , Bahar‐Fuchs, Alex , Bowman, Gene L. , Chételat, Gaël , Ciro, Carrie , Cohen, Ann D. , Dilworth‐Anderson, Peggye, Dreux, Simone, Edland, Steven D. , Esbensen, Anna J. , Ewers, Michael , Fargo, Keith N. , Fortea, Juan , González, Héctor M. , Gustafson, Deborah , Head, Elizabeth , Hendrix, James A. , Hofer, Scott M. , Johnson, Leigh , Jutten, Roos J. , Kilborn, Kerry, Martins, Ralph N. , Morris, Martha Clare , Murray, Melissa E. , Parra, Mario A. , Roe, Catherine M. , Santos, Octavio A. , Scarmeas, Nikolaos , Schneider, Lon S. , Schupf, Nicole , Sikkes, Sietske A.M. , Snyder, Heather M. , Sohrabi, Hamid R. , Strydom, André , Muñiz‐Terrera, Graciela , Teunissen, Charlotte E. , Lent, Debora Melo van , Weinborn, Michael , Wesselman, Linda M.P. , Arenaza-Urquijo, Eider, Teunissen, Charlotte E , Fortea, Juan , Murray, Melissa E , Babulal, Ganesh M. , Arenaza‐Urquijo, Eider M. , Bell, J. Simon , Brickman, Adam M. , Dodge, Hiroko Hayama , Evered, Lisbeth Anne , Gonzalez, Hector M , Lanctôt, Krista L. , Manly, Jennifer J. , Mielke, Michelle M. , Oh, Esther S , Rissman, Robert A. , Stern, Yaakov , Tang, Yi , Wilcock, Donna M. , Zetterberg, Henrik , O’Bryant, Sid E. , Head, Elizabeth , Cohen, Annie

Mayo Clinic

Alzheimer's & Dementia | December 13, 2018 | Volume: 15 | Issue: 2 | Pages: 292-312

10.1016/j.jalz.2018.09.009 | PMID 30555031 Get It

Abstract Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging population and society as a whole. With the numbers of people with ADRDs predicted to rise dramatically across the world, the scientific community can no longer neglect the need for research focusing on ADRDs among underrepresented ethnoracial diverse groups. The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART; alz.org/ISTAART ) comprises a number of professional interest areas (PIAs), each focusing on a major scientific area associated with ADRDs. We leverage the expertise of the existing international cadre of ISTAART scientists and experts to synthesize a cross‐PIA white paper that provides both a concise “state‐of‐the‐science” report of ethnoracial factors across PIA foci and updated recommendations to address immediate needs to advance ADRD science across ethnoracial populations.
Transcriptome and epigenome landscape of human cortical development modeled in organoids
Amiri, Anahita , Coppola, Gianfilippo , Scuderi, Soraya , Wu, Feinan , Roychowdhury, Tanmoy , Liu, Fuchen , Pochareddy, Sirisha , Shin, Yurae , Safi, Alexias , Song, Lingyun , Sousa, André M. M. , Crawford, Gregory E. , Šestan, Nenad , Abyzov, Alexej , Vaccarino, Flora M. , An, Joon‐Yong , Armoskus, Christoper, Beach, Thomas G., Belmont, Judson, Bendl, Jaroslav , Borrman, Tyler , Brown, Leanne, Brown, Miguel , Brown, Mimi, Brunetti, Tonya M. , Burke, Emily E., Chae, Yooree, Charney, Alexander W. , Cherskov, Adriana , Choi, Jinmyung , Clarke, Declan , Valle, Diane M. Del , Devillers, Olivia, Dracheva, Stella , Emani, Prashant S. , Evgrafov, Oleg V. , Fitzgerald, Dominic , Flatow, Elie, Francoeur, Nancy , Fullard, John F. , Gao, Tianliuyun , Geschwind, Daniel H. , Giase, Gina , Goodman, Thomas, Grennan, Kay, Gu, Mengting , Hadjimichael, Evi , Hahn, Chang-Gyu, Haroutunian, Vahram , Huey, Jack , Ivanov, Nikolay A. , Jacobov, Rivka, Jiang, Yan , Jiang, Yi , Kassim, Bibi, Kefi, Amira , Kleiman, Joel E., Knowles, James A. , Kozlenkov, Alexey , Li, Zhen , Lipska, Barbara K., Mangravite, Lara M. , Mariani, Jessica , Mattei, Eugenio , Miller, Daniel J. , Moore, J. Russell, Peters, Mette A. , Pinto, Dalila , Polioudakis, Damon, Ray, Mohana, Reddy, Timothy E. , Rhie, Suhn K. , Santpere, Gabriel , Sheppard, Brooke , Shi, Xu , Shieh, Annie W. , Shin, Joo Heon , Spitsyna, Valeria N. , Szatkiewicz, Jin , Szekely, Anna , Wang, Yongjun , Weissman, Sherman M., Weng, Zhiping , White, Kevin P. , Willsey, Jeremy A., Witt, Heather , Won, Hyejung , Xia, Yan , Xu, Min , Yang, Mo , Zandi, Peter P. , Zhang, Jing , Zharovsky, Elizabeth , Sousa, André M M , Gerstein, Mark , Crawford, Gregory E , Sestan, Nenad , Abyzov, Alexej , Vaccarino, Flora M , Del Valle, Diane M , Zhu, Ying , Gerstein, Mark , Akbarian, Schahram , Ashley‐Koch, Allison E. , Bryois, Julien , Camarena, Adrian , Carlyle, Becky Catherine , Chen, Chao , Cheng, Lijun , Collado‐Torres, Leonardo , Dai, Rujia , Torre-Ubieta, Luis de la , Farnham, Peggy , Gandal, Michael J. , Garrett, Melanie E , Girdhar, Kiran Kumar , Giusti‐Rodríguez, Paola , Goes, Fernando , Goodman, Thomas, Gürsoy, Gamze , Hauberg, Mads E. , Hoffman, Gabriel E. , Hyde, Thomas M , Jaffe, Andrew E. , Johnson, Graham D. , Kim, Yunjung , Kitchen, Robert , Li, Mingfeng , Liu, Chunyu , Liu, Shuang , Moore, Jill, Nairn, Angus C. , Navarro, Fábio C. P. , Park, Royce , Pratt, Henry , Price, Amanda J. , Purcaro, Michael J. , Roussos, Panos , Sanders, Stephan , Schreiner, Shannon , Škarica, Mario , State, Matthew W. , Sullivan, Patrick F. , Swarup, Vivek , Tao, Ran , Bakel, Harm van , Wang, Daifeng , Warrell, Jonathan , Webster, Maree J. , Werling, Donna M. , Wiseman, Jennifer R. , Wray, Gregory A. , Yang, Yucheng

Mayo Clinic

Science | December 13, 2018 | Volume: 362 | Issue: 6420 | Pages: No page available

10.1126/science.aat6720 | PMID 30545853 Get It

INTRODUCTION The human cerebral cortex has undergone an extraordinary increase in size and complexity during mammalian evolution. Cortical cell lineages are specified in the embryo, and genetic and epidemiological evidence implicates early cortical development in the etiology of neuropsychiatric disorders such as autism spectrum disorder (ASD), intellectual disabilities, and schizophrenia. Most of the disease-implicated genomic variants are located outside of genes, and the interpretation of noncoding mutations is lagging behind owing to limited annotation of functional elements in the noncoding genome. RATIONALE We set out to discover gene-regulatory elements and chart their dynamic activity during prenatal human cortical development, focusing on enhancers, which carry most of the weight upon regulation of gene expression. We longitudinally modeled human brain development using human induced pluripotent stem cell (hiPSC)–derived cortical organoids and compared organoids to isogenic fetal brain tissue. RESULTS Fetal fibroblast–derived hiPSC lines were used to generate cortically patterned organoids and to compare oganoids’ epigenome and transcriptome to that of isogenic fetal brains and external datasets. Organoids model cortical development between 5 and 16 postconception weeks, thus enabling us to study transitions from cortical stem cells to progenitors to early neurons. The greatest changes occur at the transition from stem cells to progenitors. The regulatory landscape encompasses a total set of 96,375 enhancers linked to target genes, with 49,640 enhancers being active in organoids but not in mid-fetal brain, suggesting major roles in cortical neuron specification. Enhancers that gained activity in the human lineage are active in the earliest stages of organoid development, when they target genes that regulate the growth of radial glial cells. Parallel weighted gene coexpression network analysis (WGCNA) of transcriptome and enhancer activities defined a number of modules of coexpressed genes and coactive enhancers, following just six and four global temporal patterns that we refer to as supermodules, likely reflecting fundamental programs in embryonic and fetal brain. Correlations between gene expression and enhancer activity allowed stratifying enhancers into two categories: activating regulators (A-regs) and repressive regulators (R-regs). Several enhancer modules converged with gene modules, suggesting that coexpressed genes are regulated by enhancers with correlated patterns of activity. Furthermore, enhancers active in organoids and fetal brains were enriched for ASD de novo variants that disrupt binding sites of homeodomain, Hes1, NR4A2, Sox3, and NFIX transcription factors. CONCLUSION We validated hiPSC-derived cortical organoids as a suitable model system for studying gene regulation in human embryonic brain development, evolution, and disease. Our results suggest that organoids may reveal how noncoding mutations contribute to ASD etiology. Summary of the study, analyses, and main results. Data were generated for iPSC-derived human telencephalic organoids and isogenic fetal cortex. Organoids modeled embryonic and early fetal cortex and show a larger repertoire of enhancers. Enhancers could be divided into activators and repressors of gene expression. We derived networks of modules and supermodules with correlated gene and enhancer activities, some of which were implicated in autism spectrum disorders (ASD).
Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus
Khan, Aliya , Koch, Christian A. , Uum, Stan Van , Baillargeon, Jean‐Patrice , Bollerslev, Jens, Brandi, Maria Luisa , Marcocci, Claudio , Rejnmark, Lars , Rizzoli, René , Shrayyef, Muhammad , Yıldız, Bülent Okan , Clarke, Bart, Brandi, Maria Luisa , Rejnmark, Lars , Thakker, Rajesh V. , Clarke, B.L.

Mayo Clinic

European Journal of Endocrinology | December 11, 2018 | Volume: 180 | Issue: 3 | Pages: P1-P22

10.1530/eje-18-0609 | PMID 30540559 Get It

Purpose: To provide practice recommendations for the diagnosis and management of hypoparathyroidism in adults. Methods: Key questions pertaining to the diagnosis and management of hypoparathyroidism were addressed following a literature review. We searched PubMed, MEDLINE, EMBASE and Cochrane databases from January 2000 to March 2018 using keywords ‘hypoparathyroidism, diagnosis, treatment, calcium, PTH, calcidiol, calcitriol, hydrochlorothiazide and pregnancy’. Only English language papers involving humans were included. We excluded letters, reviews and editorials. The quality of evidence was evaluated based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. These standards of care for hypoparathyroidism have been endorsed by the Canadian Society of Endocrinology and Metabolism. Results: Hypoparathyroidism is a rare disease characterized by hypocalcemia, hyperphosphatemia and a low or inappropriately normal serum parathyroid hormone level (PTH). The majority of cases are post-surgical (75%) with nonsurgical causes accounting for the remaining 25% of cases. A careful review is required to determine the etiology of the hypoparathyroidism in individuals with nonsurgical disease. Hypoparathyroidism is associated with significant morbidity and poor quality of life. Treatment requires close monitoring as well as patient education. Conventional therapy with calcium supplements and active vitamin D analogs is effective in improving serum calcium as well as in controlling the symptoms of hypocalcemia. PTH replacement is of value in lowering the doses of calcium and active vitamin D analogs required and may be of value in lowering long-term complications of hypoparathyroidism. This manuscript addresses acute and chronic management of hypoparathyroidism in adults. Main conclusions: Hypoparathyroidism requires careful evaluation and pharmacologic intervention in order to improve serum calcium and control the symptoms of hypocalcemia. Frequent laboratory monitoring of the biochemical profile and patient education is essential to achieving optimal control of serum calcium.
Conceptualising paediatric health disparities: a metanarrative systematic review and unified conceptual framework
Ridgeway, Jennifer L. , Ryn, Michelle van , Murad, M. Hassan , Asiedu, Gladys B. , Egginton, Jason S. , Beebe, Timothy J. , Finney Rutten, Lila J, van Ryn, Michelle, Griffin, Joan M. , Murad, M Hassan , Ridgeway, Jennifer L , van Ryn, Michelle , Wang, Zhen , Rutten, Lila J. Finney , Beebe, Timothy J.

Mayo Clinic

BMJ Open | December 11, 2018 | Volume: 7 | Issue: 8 | Pages: e015456

10.1136/bmjopen-2016-015456 | PMID 28780545 Get It

Objective There exists a paucity of work in the development and testing of theoretical models specific to childhood health disparities even though they have been linked to the prevalence of adult health disparities including high rates of chronic disease. We conducted a systematic review and thematic analysis of existing models of health disparities specific to children to inform development of a unified conceptual framework. Methods We systematically reviewed articles reporting theoretical or explanatory models of disparities on a range of outcomes related to child health. We searched Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus (database inception to 9 July 2015). A metanarrative approach guided the analysis process. Results A total of 48 studies presenting 48 models were included. This systematic review found multiple models but no consensus on one approach. However, we did discover a fair amount of overlap, such that the 48 models reviewed converged into the unified conceptual framework. The majority of models included factors in three domains: individual characteristics and behaviours (88%), healthcare providers and systems (63%), and environment/community (56%), . Only 38% of models included factors in the health and public policies domain. Conclusions A disease-agnostic unified conceptual framework may inform integration of existing knowledge of child health disparities and guide future research. This multilevel framework can focus attention among clinical, basic and social science research on the relationships between policy, social factors, health systems and the physical environment that impact children's health outcomes.
Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma
Miller, Kevin C. , Marinelli, John P. , Link, Michael J., Janus, Jeffrey R. , Foote, Robert L. , Price, Katharine A. , García, Joaquín J. , Rivera, Michael , Chintakuntlawar, Ashish V. , Garcia, Joaquin, Chintakuntlawar, Ashish V , Miller, Kevin C , Gompel, Jamie J. Van

Mayo Clinic

Head & Neck | December 10, 2018 | Volume: 41 | Issue: 5 | Pages: 1335-1341

10.1002/hed.25558 | PMID 30536472 Get It

AbstractBackgroundPast research established that surgery plus adjuvant radiotherapy (S + AR) improves overall survival (OS) in esthesioneuroblastoma (ENB). However, it is unknown if the addition of adjuvant chemotherapy (AC) further improves survival. The primary objective of this study was to compare survival among patients treated with S + AR alone to patients who underwent S + AR + AC.MethodsRetrospective review of patient records.ResultsThirty‐eight patients met inclusion criteria for either S + AR or S + AR + AC treatment groups. The S + AR + AC group contained more patients with Kadish stage D disease, dural invasion, and positive histologic margins postsurgery. All S + AR + AC patients received platinum‐based regimens, combined with etoposide in 67%. OS and recurrence‐free survival did not differ between the two groups, even when restricting the analysis to patients with Kadish stages B and C disease.ConclusionPatients who received platinum‐based AC did not exhibit improved survival compared to S + AR alone. Further investigation, preferably prospective, into the optimal use of systemic therapy in ENB is warranted.
RUNX1‐dependent mechanisms in biological control and dysregulation in cancer
Hong, Deli , Fritz, Andrew J. , Gordon, Jonathan A. R., Tracy, Kirsten M. , Frietze, Seth , Carr, Frances E. , Nickerson, Jeffrey A. , Wijnen, André J. van , Imbalzano, Anthony N. , Zaidi, Sayyed K. , Lian, Jane B. , Stein, Janet L. , Tracy, Kirsten M , van Wijnen, Andre J , Stein, Gary S , Tye, Coralee E. , Boyd, Joseph R. , Stein, Gary S.

Mayo Clinic

Journal of Cellular Physiology | December 5, 2018 | Volume: 234 | Issue: 6 | Pages: 8597-8609

10.1002/jcp.27841 | PMID 30515788 Get It

AbstractThe RUNX1 transcription factor has recently been shown to be obligatory for normal development. RUNX1 controls the expression of genes essential for proper development in many cell lineages and tissues including blood, bone, cartilage, hair follicles, and mammary glands. Compromised RUNX1 regulation is associated with many cancers. In this review, we highlight evidence for RUNX1 control in both invertebrate and mammalian development and recent novel findings of perturbed RUNX1 control in breast cancer that has implications for other solid tumors. As RUNX1 is essential for definitive hematopoiesis, RUNX1 mutations in hematopoietic lineage cells have been implicated in the etiology of several leukemias. Studies of solid tumors have revealed a context‐dependent function for RUNX1 either as an oncogene or a tumor suppressor. These RUNX1 functions have been reported for breast, prostate, lung, and skin cancers that are related to cancer subtypes and different stages of tumor development. Growing evidence suggests that RUNX1 suppresses aggressiveness in most breast cancer subtypes particularly in the early stage of tumorigenesis. Several studies have identified RUNX1 suppression of the breast cancer epithelial‐to‐mesenchymal transition. Most recently, RUNX1 repression of cancer stem cells and tumorsphere formation was reported for breast cancer. It is anticipated that these new discoveries of the context‐dependent diversity of RUNX1 functions will lead to innovative therapeutic strategies for the intervention of cancer and other abnormalities of normal tissues.
Office-Based Mesenchymal Stem Cell Therapy for the Treatment of Musculoskeletal Disease: A Systematic Review of Recent Human Studies
Law, Luke, Wijnen, André J. van , Eldrige, Jason S. , Mauck, William D. , Pingree, Mathew J., Yang, Juan , Muir, Casey W, Erwin, Patricia J., Bydon, Mohamad , Qu, Wenchun , van Wijnen, Andre J , Hunt, Christine , Nassr, Ahmad , Larson, A. Noelle , Muir, Casey

Mayo Clinic

Pain Medicine | December 3, 2018 | Volume: 20 | Issue: 8 | Pages: 1570-1583

10.1093/pm/pny256 | PMID 30597057 Get It

Abstract Background The use of mesenchymal stem cells (MSCs) in clinical applications for the treatment of musculoskeletal disease is steadily increasing in office-based practice. The so-called “first generation” of MSCs is defined as autologous stem cells that have undergone minimal manipulation and are used for a homologous purpose. Systematic reviews of the clinical trials completed to date of such MSCs enable practitioners to better understand what is currently known about the outcomes and side effects of such treatments. Study Design A systematic review of human clinical studies of office-based MSC therapy for the treatment of painful degenerative musculoskeletal conditions. Methods A search of the Ovid MEDLINE, EMBASE, and Scopus databases was conducted from 2006 through September 2016. Seven hundred sixty-one records were identified from database searching, and two records from reference review of included papers. Studies with human subjects that evaluated treatment of musculoskeletal disease with minimally manipulated MSCs were included. Results Eight studies were included in this review based on selection criteria. A total of 941 patients were included, 841 of whom received cellular products, and no significant adverse events were reported. Symptomatology generally improved, though no differences were seen over controls where present. Conclusion Support in the literature is strongest for the use of bone marrow aspirate concentrate (BMAC) injections for the treatment of knee pain, but applications of the use of BMAC and peripheral blood–derived MSCs for the treatment of hip pain, tendon pain, and disc pain have all been reported. Further research is required, with large randomized controlled trials.